Trevi Therapeutics Files 8-K with Material Agreements
Ticker: TRVI · Form: 8-K · Filed: Apr 17, 2026 · CIK: 0001563880
Sentiment: neutral
Topics: material-agreement, financial-results, corporate-filing
TL;DR
TREVI filed an 8-K on 4/17/26 detailing material agreements and financial results.
AI Summary
Trevi Therapeutics, Inc. filed an 8-K on April 17, 2026, reporting on a material definitive agreement, results of operations, and other events. The filing includes various exhibits such as financial statements and legal opinions, indicating significant corporate activity. The company is involved in the pharmaceutical preparations sector.
Why It Matters
This 8-K filing signals important corporate developments and potential strategic moves by Trevi Therapeutics, which could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant information, but without specific details on the agreements or financial results, the immediate risk level is moderate.
Key Numbers
- 0001563880 — CIK Number (Identifies Trevi Therapeutics, Inc. in SEC filings.)
- 2026-04-17 — Filing Date (Date the 8-K was accepted by the SEC.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the 8-K
- 0001563880 (company) — CIK number for Trevi Therapeutics, Inc.
- 2026-04-17 (date) — Filing Date of the 8-K
- 2026-04-16 (date) — Period of Report for the 8-K
FAQ
What is the nature of the material definitive agreement mentioned in Item 1.01?
The filing indicates an 'Entry into a Material Definitive Agreement' under Item 1.01, but the specific details of this agreement are not provided in the summary information.
What were the key results of operations and financial condition reported in Item 2.02?
Item 2.02 pertains to 'Results of Operations and Financial Condition,' but the specific financial details are not elaborated upon in the provided filing summary.
Are there any other significant events reported under Item 8.01?
Item 8.01 covers 'Other Events,' and the filing confirms its inclusion, suggesting other relevant corporate announcements were made.
What types of exhibits are included with this 8-K filing?
The filing includes exhibits such as EX-1.1, EX-5.1, EX-99.1, and various XBRL documents, along with graphic files.
What is Trevi Therapeutics, Inc.'s primary business sector?
Trevi Therapeutics, Inc. is categorized under SIC code 2834, which corresponds to Pharmaceutical Preparations, and is further classified within the Life Sciences sector.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2026 regarding Trevi Therapeutics, Inc. (TRVI).